Mab 14G2a

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameMab 14G2a

Drug Alias NameMab 14G2a14G2a

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murine

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsDisialoganglioside GD2 inhibitors

TargetsDisialoganglioside GD2

Therapy Area/IndicationsMelanomaNeuroblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNational Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNational Cancer Institute

Active IndicationsN/A

Inactive IndicationsMelanomaNeuroblastoma

Other Information

ATC CodeN/A